PMID- 34176835
OWN - NLM
STAT- MEDLINE
DCOM- 20220105
LR  - 20220216
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 61
IP  - 1
DP  - 2022 Jan 1
TI  - Severe Hypomagnesemia Associated with the Long-term Use of the 
      Potassium-competitive Acid Blocker Vonoprazan.
PG  - 119-122
LID - 10.2169/internalmedicine.7325-21 [doi]
AB  - Hypomagnesemia caused by a proton pump inhibitor (PPI) was first reported in 
      2006. We herein report a case of hypomagnesemia due to the long-term use of 
      vonoprazan, a potassium-competitive acid blocker (P-CAB). A 66-year-old man was 
      admitted to our hospital complaining of disturbance of consciousness with 
      evidence of hypomagnesemia noted on blood testing. The long-term use of 
      vonoprazan was considered the cause of his hypomagnesemia, so it was 
      discontinued, after which the hypomagnesemia improved. Hypomagnesemia can be 
      induced not only by PPI treatment but also following the long-term use of P-CAB.
FAU - Okamoto, Masaru
AU  - Okamoto M
AD  - Department of General Internal Medicine, Tottori Prefectural Central Hospital, 
      Japan.
FAU - Wakunami, Yu
AU  - Wakunami Y
AD  - Department of General Internal Medicine, Tottori Prefectural Central Hospital, 
      Japan.
FAU - Hashimoto, Kyoji
AU  - Hashimoto K
AD  - Department of General Internal Medicine, Tottori Prefectural Central Hospital, 
      Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20210626
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 
      (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Pyrroles)
RN  - 0 (Sulfonamides)
RN  - RWP5GA015D (Potassium)
SB  - IM
MH  - Aged
MH  - Humans
MH  - Male
MH  - *Potassium
MH  - Proton Pump Inhibitors/adverse effects
MH  - *Pyrroles/adverse effects
MH  - Sulfonamides/adverse effects
PMC - PMC8810260
OTO - NOTNLM
OT  - hypomagnesemia
OT  - potassium-competitive acid blocker
OT  - vonoprazan
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2021/06/29 06:00
MHDA- 2022/01/06 06:00
PMCR- 2022/01/01
CRDT- 2021/06/28 05:42
PHST- 2021/06/29 06:00 [pubmed]
PHST- 2022/01/06 06:00 [medline]
PHST- 2021/06/28 05:42 [entrez]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.2169/internalmedicine.7325-21 [doi]
PST - ppublish
SO  - Intern Med. 2022 Jan 1;61(1):119-122. doi: 10.2169/internalmedicine.7325-21. Epub 
      2021 Jun 26.